Wanner, C
Kamalmaz N, Ben Bacha A, Alonazi M, Albasher G, Khayyat AIA, El-Ansary A
FOXO4-DRI acts as a competitive inhibitor of this interaction binding directly to the transactivation domain 2 (TAD2) of p53, displacing FOXO4, and allowing phosphorylated p53 to be exported from the nucleus and directed to mitochondria, where it activates BAX, triggers caspase-3 cleavage (via the p53/BCL-2/Caspase-3 signalling pathway), and drives cell-intrinsic apoptosis
It's often paired with BPC-157, in what users refer to as the "Wolverine stack." Similar to the presentations for BPC-157 and KPV, advocates for this peptide acknowledged the lack of rigorous clinical data
Shots for energy work faster than most people think
The rapid release of this product is generally applied to those cases where support is needed in the upper gastrointestinal region as well as when more acute needs arise with regard to joint support